Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials

BACKGROUND: Cilostazol is an oral antiplatelet agent currently indicated for treatment of intermittent claudication. There is evidence that cilostazol may reduce femoropopliteal restenosis after percutaneous endovascular intervention. METHODS: We searched PubMed, Scopus and Cochrane databases from 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Heart
Main Authors: Benjo, Alexandre M, Garcia, Daniel C, Jenkins, J Stephen, Cardoso, Rhanderson M N, Molina, Taina P, El-Hayek, Georges E, Nadkarni, Girish N, Aziz, Emad F, Dinicolantonio, James J, Collins, Tyrone
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2014
Assuntos:
Meta-Analysis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225296/
https://ncbi.nlm.nih.gov/pubmed/25392738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2014-000154
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados